Sector News

B-MS to build near-$1 billion biologics facility in Ireland

November 14, 2014
Life sciences
Bristol-Myers Squibb has unveiled plans to construct a new biologics manufacturing facility in Ireland which will create up to 400 new jobs as part of a near $1 billion investment.
 
The 30,000-square metre project will house six bioreactors and a purification area as well as office and laboratory space. It will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant in Cruiserath, Co Dublin.
 
B-MS said the full cost is anticipated to be “comparable to the approximately $900 million investment to construct and operationalise the company’s biologics manufacturing facility in Devens, Massachusetts”. Some 350-400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the plant which is estimated to be operational in 2019.
 
Taoiseach Enda Kenny said the news “is a huge boost to the Irish economy”, noting that 1,000 construction jobs will also be created in the initial phase. He added that the government “has a plan to secure recovery so that Ireland can attract new jobs and investments”.
 
B-MS chief executive Lamberto Andreotti said the investment “reflects the strength of our business and the increasingly important role that biologic medicines will play” in the firm’s future. He noted that “for 50 years, B-MS has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy”.
 
By Kevin Grogan
 
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach